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Objective To evaluate macular function using multimodality in eyes with age-related macular degeneration (AMD) at 17 
various stages. 18 
Methods Macular function in 20 control eyes (20 subjects), 17 eyes (17 patients) with large drusen, 18 eyes (18 19 
patients) with drusenoid pigment epithelial detachment (PED), and 19 eyes (19 patients) with neovascular AMD was 20 
examined using a Landolt chart for visual acuity; retinal sensitivity was measured by microperimetry; and focal 21 
macular electroretinography (fmERG) was performed. In all of these eyes, retinal morphology was examined using 22 
optical coherence tomography. 23 
Results Eyes with neovascular AMD showed morphologic changes in the neurosensory retina as well as marked 24 
deterioration of macular function in all parameters measured with a Landolt chart, fmERG, and microperimetry. Eyes 25 
with large drusen showed only minimal morphologic changes in the neurosensory retina. In this large drusen group, 26 
although retinal sensitivity at the central point was significantly decreased (P = 0.0063), the other parameters of 27 
macular function were well preserved. In eyes with drusenoid PED, the structure of the neurosensory retina was well 28 
preserved, while the foveal thickness was significantly increased (P = 0.013). The macular function of these eyes 29 
was significantly deteriorated, with the VA, amplitude of the a-wave and b-wave, and retinal sensitivity being 30 
markedly decreased. In addition, the area of PED correlated with the latency of the a- wave and b-wave and with the 31 
retinal sensitivity within the central 4° or 8° region. 32 
Conclusion Multimodal evaluation demonstrated a significant decrease in macular function in drusenoid PED and in 33 
 3 
 
neovascular AMD. 34 
Keywords: Age-related macular degeneration, Drusenoid pigment epithelial detachment, Drusen, Focal macular 35 





Age-related macular degeneration (AMD) is one of the leading causes of visual impairment and an intensive 39 
therapeutic target in developed countries [1-6]. Drusen or drusenoid pigment epithelium detachment (PED), which is 40 
a prodrome lesion of advanced AMD, does not usually cause a severe loss of visual acuity (VA), but it is the 41 
subsequent development of choroid neovascularization (CNV) that so often causes the central visual disturbance. So 42 
far, however, visual impairment due to AMD has been evaluated primarily by VA measurement alone. Indeed, VA 43 
measurement is essential to evaluate visual function, but it reflects only foveal function. Lesions of AMD, including 44 
drusen, CNV, serous retinal detachment, subretinal hemorrhage, and PED, are seen not only beneath the fovea but in 45 
the larger macular area, which leads to the macular dysfunction.[7] 46 
     To evaluate visual function of the entire macular area, simultaneous use of the focal macular electroretinogram 47 
(fmERG) and of microperimetry have recently been reported [8, 9]. The fmERG enables measurement of macular 48 
function throughout its entirety, even in patients with poor fixation, by monitoring through an infrared camera and 49 
manual adjustment of the stimulus to the macular area [10]. Microperimetry allows functional evaluation of selected 50 
points throughout the macular area [11, 12]. During this test, the autotracking function corrects for shifts in the 51 
measurement position caused by small, involuntary movements. Recent studies using microperimetry have shown 52 
that early or advanced AMD often accompanies the severe reduction in sensitivity of the macular area [13-21]. With 53 
the use of microperimetry, Yodoi et al reported a functional reduction in the macular area of eyes with subfoveal 54 
polypoidal choroidal vasculopathy (PCV), which is a variant of neovascular AMD [22]. In their report, macular 55 
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function improved after photodynamic therapy with concomitant recovery of the subjective symptoms, despite there 56 
being no improvement in VA. 57 
     Other recent studies with microperimetry or ERG have evaluated macular function in eyes with AMD and 58 
have reported that it is impaired—even in eyes with drusen alone [23, 24]. Indeed, each modality has both 59 
advantages and limitations. To evaluate visual function effectively, it would be of help to measure retinal function 60 
within the macular area using the multimodality approach. So far, however, little information is available on the 61 
multimodal evaluation of visual function in eyes with AMD. Therefore, this study was designed to evaluate the 62 
macular function using multimodality in eyes with AMD at various stages, including those with large drusen, 63 
drusenoid PED, and those with neovascular AMD. 64 
 65 
Patients and methods 66 
In this prospective study, we performed multimodal evaluation of macular function in eyes with AMD at various 67 
stages; the eyes comprised 17 (17 patients) with large drusen, 18 (18 patients) with drusenoid PED, and 19 (19 68 
patients) with neovascular AMD (8 eyes with typical AMD and 11 eyes with polypoidal choroidal vasculopathy). 69 
Eyes with large drusen were judged by the presence of multiple large drusen (>125 µm) within 3000 µm of the 70 
center of the macula on fundus photographs. The diagnostic criteria of drusenoid PED were confluent drusen, with a 71 
focal area of PED involving the macular area, with a minimum size of 1/2 disc diameter [25], and without CNV 72 
detected on ophthalmoscopy or fluorescein and indocyanine green angiography. Neovascular AMD was diagnosed 73 
 6 
 
on the basis of fluorescein and indocyanine green angiography, which showed an exudative change with CNV. In the 74 
current study, eyes with central geographic atrophy were excluded. We also recruited 20 eyes (20 subjects) as an 75 
age-adjusted control group. The criteria for the eyes, including for the control eyes, were as follows: ≥1.0 VA on a 76 
Landolt chart, <10 small drusen (<63 µm) within 3000 µm of the center of the macula on the fundus photograph, 77 
normal morphology of the fovea as seen with optical coherence tomography (OCT), and absence of central 78 
geographic atrophy or CNV. 79 
This study was approved by the institutional review board of Kyoto University Graduate School of 80 
Medicine and adhered to the tenets of the Declaration of Helsinki. Written informed consent for research 81 
participation was obtained from each subject before examination. 82 
     Each subject underwent a comprehensive ophthalmologic examination, including measurement of 83 
best-corrected VA on a Landolt chart, determination of intraocular pressure, indirect ophthalmoscopy, and slit-lamp 84 
biomicroscopy with a contact lens. In each subject, 45º digital fundus photographs were obtained using a digital 85 
fundus camera (TRC-50LX; Topcon, Tokyo, Japan; 3216 × 2136 pixels) after pupil dilatation and the macular area 86 
was examined with a Spectralis HRA+OCT device (Heidelberg Engineering, Heidelberg, Germany). Each patient 87 
with large drusen, drusenoid PED, or neovascular AMD underwent fluorescein and indocyanine green angiography 88 
with a confocal laser scanning system (HRA-2; Heidelberg Engineering). In each eye, macular function was 89 
examined by fundus-monitored microperimetry and fmERG recording. 90 
     Retinal sensitivity within the macular area was examined with a fundus-monitored microperimeter (Micro 91 
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Perimeter 1 [MP1]; Nidek, Gamagori, Japan). A 4-2-staircase strategy with Goldmann III-sized stimuli was used, and 92 
57 stimulus locations within a 10° radius were examined by microperimetry. Each stimulus was located according to 93 
the measurement points on the Humphrey 10-2, with some additional points. The white background illumination was 94 
set at 1.27 cd/m2. The differential luminance, defined as the difference between the stimulus luminance and 95 
background luminance, was 127 cd/m2 at 0-dB stimulation, and the maximum stimulus attenuation was 20 dB. The 96 
stimulus duration was 200 milliseconds (ms), and the fixation target varied in size according to the VA of the patient. 97 
There were 17 and 37 measurement points within the central circles with radii of 4° and 8°, respectively. 98 
     The fmERG recording procedure has been previously described in detail [8, 9]. Briefly, after maximal 99 
dilatation of the pupils of both eyes, a Burian-Allen bipolar contact lens electrode (Hansen Ophthalmic Laboratories, 100 
Iowa City, IA, USA) was placed in the conjunctival sac of each eye under topical anesthesia. A chloride silver 101 
electrode was attached to the left earlobe to serve as the ground electrode. The fmERG was elicited by circular 102 
stimuli positioned on the macular area, using a prototype of the ER-80 (Kowa, Tokyo, Japan), which consisted of an 103 
infrared camera (Kowa) and a stimulation system (Mayo Corporation, Nagoya, Japan). The luminance values of the 104 
white stimulus light and the background illumination were 181.5 and 6.9 cd/m2, respectively. The stimulus within the 105 
7.5°-radius circle was centered on the fovea, as observed through the infrared camera. The fmERG was recorded 106 
using 5-Hz rectangular stimuli (100 ms with the light on and 100 ms with the light off). The recording (200 107 
responses) was carried out in triplicate to confirm the reproducibility of the results, so a total of 600 responses were 108 
averaged by the signal processor (Neuropack MEB-2204; Nihon Kohden, Tokyo, Japan). The fmERG response was 109 
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digitized at 10 kHz with a band-pass filter of 5–500 Hz for the a-wave and the b-wave. The amplitudes of the a- and 110 
b-waves were measured from baseline to the peak of the a-wave and from the trough of the a-wave to the peak of the 111 
b-wave, respectively. Latency was defined as the time from the beginning of stimulation to the peak of each 112 
component. 113 
     For the OCT images, the foveal thickness in each eye was determined in the following 2 ways: the distance 114 
between the internal limiting membrane (ILM) and the outer border of the RPE or the distance between the ILM and 115 
the Bruch membrane. In eyes with drusenoid PED, we also measured the height and area of the PED. For the 116 
sequential OCT images, the height of the PED was defined as the maximal distance between the outer border of the 117 
RPE and the Bruch membrane (sometimes outside the fovea). For the late-phase indocyanine green angiogram, the 118 
area of the PED was measured using software built into the HRA-2. Briefly, drusenoid PED was observed as a dark 119 
area on the late-phase indocyanine green angiogram, and the edge of this central dark area was traced manually. The 120 
surrounding small dark lesions (drusen) isolated from the central PED were not included. 121 
     Statistical analysis was performed using PASW Statistics version 17.0 software (SPSS, Chicago, IL, USA). All 122 
values were expressed as means ± standard deviations. The best-corrected VA was measured using a Landolt chart 123 
and converted to the logarithm of the minimum angle of resolution (logMAR). To clarify differences from the 124 
healthy controls, all mean values between groups were compared using 1-way analysis of variance and post hoc  125 





Table 1 shows the characteristics of the study populations. Although the controls (82.0 ± 3.2 years) were significantly 129 
older than the patients with neovascular AMD (77.3 ± 6.9 years, P = 0.019), there was no significant difference in the 130 
gender or lens status of groups. In the control group, 13 eyes had small drusen in the macular area and 7 had no 131 
drusen. All eyes showed good macular function (Fig. 1). 132 
     All functional parameters were measured, with VA, fmERG, and microperimetry showing significant variation 133 
between the groups (Table 1). All eyes with neovascular AMD showed marked morphologic changes in the 134 
neurosensory retina. In this group, cystoid macular edema was seen in 4 eyes (21%), serous retinal detachment, in 14 135 
eyes (74%), and PED, in 17 eyes (89%); foveal thickness of the neurosensory retina (384 ± 256 µm) was 136 
significantly increased compared with the control eyes (224 ± 27 µm) (Fig. 2). Consistent with these morphologic 137 
changes, macular function (VA, fmERG, and microperimetry) was significantly deteriorated in the neovascular AMD 138 
group (Figs. 3 and 4). 139 
     In the large drusen group, all eyes showed multiple large drusen in the macular area; the mean number of 140 
drusen measuring 125 to 250 µm was 10.3 ± 4.2 and that of drusen measuring at least 250 µm was 3.1 ± 2.1. These 141 
eyes showed minimal morphologic changes in the neurosensory retina. No eyes in this group showed cystoid 142 
macular edema, serous retinal detachment, or a vitelliform lesion. Foveal thickness of the neurosensory retina (196 ± 143 
40 µm) was no different from that in the control group (Fig. 2). In this large drusen group, while retinal sensitivity at 144 
the central point was significantly decreased, the other parameters of macular function (VA, fmERG, and 145 
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microperimetry) were preserved (Figs. 3 and 5). 146 
     In the drusenoid PED group, all eyes had drusenoid PED of at least 1/2 disc diameter within the macular area. 147 
The mean area of the PED was 4.78 ± 3.74 mm2 and the mean height was 266 ± 178 µm. In eyes with drusenoid 148 
PED, the foveal thickness between the ILM and the Bruch membrane (377 ± 164 µm) was significantly greater than 149 
that in the control eyes (224 ± 27 µm, P = 0.013). However, the structure of the neurosensory retina was well 150 
preserved, and the foveal thickness between the ILM and RPE (200 ± 49 µm) did not differ from that in the control 151 
group (Fig. 2). On the other hand, the macular function of these eyes was significantly deteriorated. VA, amplitude of 152 
the a-wave and of the b-wave, and retinal sensitivity measured with the MP1 were significantly decreased when 153 
compared with the control eyes (Figs. 3 and 6). Table 2 shows the correlation between the size of the drusenoid PED 154 
and macular function and between the area of the PED and the latency of the a-wave and the b-wave, and retinal 155 
sensitivity within the central 4° or 8°. The height of the PED was negatively correlated with retinal sensitivity within 156 
the central 4° and 8° areas (Fig. 7). 157 
 158 
Discussion 159 
Eyes with neovascular AMD often have a severe decrease in VA. In addition, because such eyes often show serous 160 
retinal detachment, subretinal hemorrhage, retinal edema, or PED in the macular area, they may well have a 161 
reduction in function in the macular area. With the use of fmERG, Nishihara et al reported that, in eyes with 162 
neovascular AMD, the amplitude of each wave was reduced to 29% to 35% of that of the control eyes [26]. With the 163 
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use of microperimetry, Sulzbacher et al [24] and Hautamäki et al [27] reported more recently that retinal sensitivity 164 
was markedly decreased within the area of CNV, macular edema, hemorrhage, subretinal fluid, or PED in eyes with 165 
neovascular AMD. In our patients with neovascular AMD, cystoid macular edema was seen in 21%, serous retinal 166 
detachment was seen in 74%, and PED was seen in 89% of the patients, and thickness of the fovea in the 167 
neurosensory retina was significantly increased. In eyes with neovascular AMD, severe macular dysfunction is based 168 
on the morphologic changes caused by the exudative change resulting from the CNV. 169 
     Eyes with drusen often maintain good VA. However, as the number or size of the drusen increases, they may 170 
cause a functional disturbance in the macular area. So far, several electrophysiologic assessments have been 171 
performed to study the macular function in eyes with drusen [23, 28-33]. Falsini et al documented an abnormality of 172 
the focal ERG threshold in eyes with more than 20 soft drusen [33], although they did not investigate the correlation 173 
between each drusen and the local sensitivity loss. With the use of microperimetry, Midena et al reported that retinal 174 
sensitivity in eyes with large drusen (>125 µm) was severely deteriorated[16]. Iwama et al reported that eyes with 175 
confluent soft drusen often show focal areas with reduced retinal function consistent with irregularity of the RPE line 176 
or of the junction between the inner and outer segments of the photoreceptors [34]. In the current study, while retinal 177 
sensitivity at the central point was significantly decreased in eyes with large drusen, the other parameters of macular 178 
function (VA, fmERG, and microperimetry) were well preserved. Although we did not assess function at each point, 179 
retinal function may be focally deteriorated, consistent with the drusen. In addition, the area in which drusen are seen 180 
may be involved in the reduction of macular function. 181 
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     Drusenoid PED refers to a fairly well-circumscribed, shallow elevation of the RPE formed by confluent soft 182 
drusen, often located in the center of the macula [35]. VA in eyes with drusenoid PED is reported to be relatively 183 
good. In fact, in a recent report from the Age-Related Eye Disease Study, baseline VA in eyes with drusenoid PED 184 
was ~20/32, with ~90% of eyes having VA better than 20/40 [35]. So far, however, little information is available on 185 
the macular dysfunction caused by drusenoid PED. In the current study, VA, amplitude of the a-wave and b-wave, 186 
and retinal sensitivity measured with the MP1 were significantly decreased when compared with the control eyes. In 187 
addition, the area and height of the PED were correlated with the fmERG and with the retinal sensitivity within the 188 
macular area—correlations that are consistent with the previously mentioned report of confluent drusen [34]. 189 
Photoreceptor damages, which could be observed as discontinuity of the junction of the inner and outer segments and 190 
as presence of hyperreflective foci in the OCT image (Fig. 6) [36, 37], might result in decreased macular function in 191 
eyes with drusenoid PED. Falsini et al also discussed that focal ERG sensitivity loss in eyes with drusen might result 192 
from photoreceptor drop out [33], as could be slightly seen in the OCT images of eyes with large drusen in our study 193 
(Fig. 5). 194 
    The prognosis of drusenoid PED was initially thought to be relatively good [38, 39]; however, a recent cohort 195 
study reported a high rate of progression to more advanced AMD [35]. Roquet et al documented that presence of 196 
metamorphopsia and drusenoid PED of greater than 2 disc diameters were risk factors of CNV occurrence within 2 197 
years [25]. Recently, other research groups have reported results of pilot studies on the early treatment of drusenoid 198 
PED without CNV by photodynamic therapy or by antivascular endothelial growth factor therapy [40-43]. 199 
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Gallego-Pinazo et al successfully treated 6 patients with drusenoid PED using intravitreal ranibizumab.[41] 200 
However, Krishnan and Lochhead reported rapid development of geographic atrophy after intravitreal injection of 201 
pegaptanib in an eye with drusenoid PED [42]. In a recent report from the Age-Related Eye Disease Study, 19% of 202 
eyes with drusenoid PED developed central geographic atrophy and 23% of these developed neovascular AMD [35]. 203 
When geographic atrophy develops in the extrafoveal region, VA measurement does not reflect a visual disturbance. 204 
The effect of treatment for drusenoid PED remains controversial. Multimodal measurements of macular function 205 
would be most helpful to evaluate the treatment efficacy of drusenoid PED. 206 
     There are various limitations to the current study. First, the eligible patients and controls in this study were all 207 
Japanese, and the genetic background may well have influenced the characteristics of AMD, so our results should be 208 
confirmed in another population. Second, the sample size of each group was small, so it is possible that we did not 209 
detect small differences between groups. Third, the current study excluded central geographic atrophy, primarily 210 
because this is a relatively rare feature of AMD in Japanese patients. Finally, this was a cross-sectional study, so we 211 
could not offer any information regarding changes in macular function over time. Further longitudinal studies are 212 
necessary to fully elucidate the macular function in eyes with AMD of various stages and to study the treatment 213 
effects and the natural course of eyes with AMD, especially those with AMD in the early stage. Multimodal 214 
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Figure Legends 329 
 330 
Fig. 1  Macular function in a healthy control eye. Retinal sensitivity map obtained by microperimetry (a) and focal 331 
macular electroretinogram (b). White arrowhead = beginning of stimulus; yellow arrow = amplitude of each wave of 332 
focal macular electroretinogram 333 
 334 
Fig. 2  Foveal thickness of control eyes, eyes with large drusen, eyes with drusenoid pigment epithelial detachment, 335 
and eyes with neovascular age-related macular degeneration. *P < 0.05, †P < 0.01, ‡P < 0.0001, compared with 336 
control eyes. P values were calculated by the Dunnet test. ILM indicates internal limiting membrane; RPE, retinal 337 
pigment epithelium; PED, pigment epithelium detachment; AMD, age-related macular degeneration 338 
 339 
Fig. 3  Macular function measured with multimodality in control eyes, eyes with large drusen, eyes with drusenoid 340 
pigment epithelial detachment, and eyes with neovascular age-related macular degeneration. *P < 0.05, †P < 0.01, 341 
‡P < 0.0001, as compared with control eyes. P values were calculated by the Dunnet test. LogMAR indicates 342 
logarithm of the minimum angle of resolution; PED, pigment epithelium detachment; AMD, age-related macular 343 
degeneration 344 
 345 
Fig. 4  Macular function in an eye with neovascular age-related macular degeneration. (a). Fundus photograph 346 
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shows submacular hemorrhage (0.15 on a Landolt chart, OD). (b, c) Fluorescein and indocyanine green angiograms 347 
reveal subfoveal choroidal neovascularization. Horizontal (d) and vertical (e) sections obtained with OCT show 348 
subretinal fluid. (f) Retinal sensitivity map obtained with microperimetry shows a substantial reduction of retinal 349 
sensitivity in the macular function. (g) Focal macular electroretinogram shows a substantial reduction in amplitude of 350 
all waves. Arrowhead = beginning of stimulus 351 
 352 
Fig. 5  Macular function in an eye with large drusen. (a) Fundus photograph shows multiple large drusen in the 353 
macular area (1.0 on a Landolt chart, OD). (b, c) Fluorescein and indocyanine green angiograms reveal no choroidal 354 
neovascularization. Horizontal (d) and vertical (e) sections obtained with OCT show multiple large drusen beneath 355 
and affecting the fovea. The junction of the inner and outer segments of photoreceptors (between the arrows) was 356 
discontinued. (f) Microperimetry shows preserved retinal sensitivity within the macular area except for the fovea. (g) 357 
Focal macular electroretinogram shows that the amplitude of all of the waves was relatively preserved. Arrowhead = 358 
beginning of stimulus 359 
 360 
Fig. 6  Macular function in an eye with drusenoid pigment epithelial detachment (PED). (a) Fundus photograph of 361 
drusenoid PED under the fovea (0.7 on a Landolt chart, OD). (b) Fluorescein angiogram reveals no choroidal 362 
neovascularization. (c) From the late-phase indocyanine green angiogram, the area of drusenoid PED was calculated 363 
as 6.26 mm2. Horizontal (d) and vertical (e) sections obtained with OCT show drusenoid PED. The height of the 364 
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PED was 258 µm. The red arrow indicates hyperreflective foci. (f) Retinal sensitivity map obtained with 365 
microperimetry shows a marked reduction in retinal sensitivity consistent with drusenoid PED. (g) In the focal 366 
macular electroretinogram, the amplitude of each wave was reduced to 60% - 75% of normal amplitudes. Arrowhead 367 
= beginning of stimulus 368 
 369 
Fig. 7  Scattergram of the size of the drusenoid pigment epithelial detachment and macular functions measured with 370 





TABLE 1. Background, foveal thickness, and macular function of control eyes, eyes with large drusen, eyes with drusenoid pigment 
epithelial detachment, and eyes with neovascular age-related macular degeneration. 
 Controls Large Drusen Drusenoid PED Neovascular AMD P value  
Sex (male/female) 16/4 11/6 18/0 16/3 0.054 
Phakia/pseudophakia 14/6 9/8 13/5 12/7 0.627 
Age, y 82.0 ± 3.2 80.7 ± 5.2 78.9 ± 5.0 77.3 ± 6.9 0.040 
Visual acuity, logMAR -0.07 ± 0.07 0.05 ± 0.14 0.16 ± 0.18 0.42 ± 0.42 < 0.0001 
Foveal thickness, µm      
     ILM to RPE 224 ± 27 196 ± 40 200 ± 49 384 ± 256 < 0.0001 
     ILM to Bruch membrane 224 ± 27 231 ± 36 377 ± 164 533 ± 263 < 0.0001 
Amplitude of fmERG, µV      
     a-wave 1.73 ± 0.65 1.35 ± 0.49 1.21 ± 0.67 0.87 ± 0.58 0.0005 
     b-wave 3.14 ± 0.89 2.55 ± 0.91 2.20 ± 1.09 1.37 ± 1.04 < 0.0001 
Latency of fmERG, ms      
     a-wave 23.18 ± 1.28 23.67 ± 1.58 24.39 ± 1.77 25.76 ± 3.39 0.040 
     b-wave 42.05 ± 2.27 45.44 ± 3.87 45.22 ± 3.71 48.87 ± 7.38 0.0005 
Retinal sensitivity, dB      
     center point 14.78 ± 3.52 9.94 ± 3.86 3.82 ± 3.43 5.37 ± 6.31 < 0.0001 
     within 4° 16.50 ± 2.01 13.35 ± 3.57 6.83 ± 4.39 5.78 ± 6.27 < 0.0001 
     within 8° 16.13 ± 2.10 13.66 ± 3.32 9.19 ± 3.94 6.76 ± 6.23 < 0.0001 
PED pigment epithelium detachment, AMD age-related macular degeneration, fmERG focal macular electroretinogram, ILM internal 





TABLE 2. Correlation between size of drusenoid pigment epithelium detachment and macular function. 
 Area of Drusenoid PED Height of Drusenoid PED 
 r P value r P value 
Visual acuity in logMAR  0.058 0.820 0.432  0.074 
Amplitude of fmERG     
    a-wave  -0.427 0.077 -0.118  0.642 
    b-wave  -0.445 0.067 -0.312  0.207 
Latency of fmERG     
    a-wave  0.635 0.006 -0.090  0.732 
    b-wave  0.530 0.029 0.100  0.702 
Retinal sensitivity     
    center point  -0.472 0.056 -0.423  0.091 
    within 4°  -0.682 0.003 -0.625  0.007 
    within 8°  -0.761 0.0004 -0.533  0.028 
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